Basaglar(insulin glargine injection)

Long-acting insulin for type 1 diabetes adults and children 6+; type 2 diabetes adults. Biosimilar to Lantus.

2 DTP programs

From As low as $35/mo

1 platform

FDA-Approved Indications

Glycemic control in adults and pediatric patients with type 1 diabetes and adults with type 2 diabetes

Available direct-to-patient (DTP) programs

Sorted by price, lowest first. Always verify eligibility and pricing directly with the manufacturer.

Lowest price option

via LillyDirect · Eli Lilly

As low as $35/mo

$35/mo with commercial insurance. Max $16,000/yr savings. Up to 16 fills/yr (with coverage) or 14/yr (without). Card expires 12/31/2026.

Eligibility

Commercial insurance required. Age 18+. US resident or territory. CA/MA biosimilar substitution exemptions apply.

Some benefits may not be available in: MA, CA

Last verified: Mar 2026

via LillyDirect · Eli Lilly

As low as $35/mo

$35/mo — no insurance required. Max savings up to full retail price per fill. Up to 14 fills/year. Card expires 12/31/2026.

Eligibility

No insurance required. Age 18+. US resident or territory. CA/MA biosimilar substitution exemptions apply. Government beneficiaries excluded.

Some benefits may not be available in: MA, CA

Last verified: Mar 2026

Not sure which Basaglar program fits your situation?